(0.00%) 5 187.67 points
(0.44%) 39 056 points
(-0.18%) 16 303 points
(0.54%) $79.42
(-0.14%) $2.18
(-0.06%) $2 320.80
(0.47%) $27.73
(0.73%) $991.80
(0.03%) $0.930
(0.08%) $10.90
(0.02%) $0.800
(0.01%) $91.74
-0.91% INR 5 266.00
Live Chart Being Loaded With Signals
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, distributes, and markets pharmaceutical products in India and internationally...
Stats | |
---|---|
Today's Volume | 2 089.00 |
Average Volume | 19 439.00 |
Market Cap | 131.65B |
EPS | INR0 ( 2024-02-08 ) |
Next earnings date | ( INR0 ) 2024-05-28 |
Last Dividend | INR16.00 ( 2023-07-14 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 94.81 |
ATR14 | INR9.94 (0.19%) |
Volume Correlation
AstraZeneca Pharma India Correlation
10 Most Positive Correlations | |
---|---|
SEYAIND.NS | 0.834 |
10 Most Negative Correlations | |
---|---|
CONTROLPR.NS | -0.807 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
AstraZeneca Pharma India Correlation - Currency/Commodity
AstraZeneca Pharma India Financials
Annual | 2022 |
Revenue: | INR10.03B |
Gross Profit: | INR5.45B (54.37 %) |
EPS: | INR39.72 |
FY | 2022 |
Revenue: | INR10.03B |
Gross Profit: | INR5.45B (54.37 %) |
EPS: | INR39.72 |
FY | 2022 |
Revenue: | INR8.06B |
Gross Profit: | INR4.48B (55.63 %) |
EPS: | INR24.60 |
FY | 2021 |
Revenue: | INR8.09B |
Gross Profit: | INR4.78B (59.12 %) |
EPS: | INR37.30 |
Financial Reports:
No articles found.
AstraZeneca Pharma India Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR8.00 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR16.00 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR3.70 | 2003-04-17 |
Last Dividend | INR16.00 | 2023-07-14 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 16 | -- |
Total Paid Out | INR184.10 | -- |
Avg. Dividend % Per Year | 0.19% | -- |
Score | 1.47 | -- |
Div. Sustainability Score | 4.66 | |
Div.Growth Potential Score | 2.21 | |
Div. Directional Score | 3.44 | -- |
Year | Amount | Yield |
---|---|---|
2003 | INR0 | 0.00% |
2004 | INR0 | 0.00% |
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR0 | 0.00% |
2019 | INR1.000 | 0.07% |
2020 | INR2.00 | 0.08% |
2021 | INR2.00 | 0.04% |
2022 | INR8.00 | 0.26% |
2023 | INR16.00 | 0.48% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SSWL.NS | Dividend Junior | 2023-08-14 | Annually | 20 | 0.30% | |
MRF.NS | Dividend Knight | 2023-07-20 | Semi-Annually | 23 | 0.11% | |
HGINFRA.NS | Dividend Junior | 2023-08-14 | Sporadic | 7 | 0.13% | |
BLISSGVS.NS | Dividend Junior | 2023-07-12 | Annually | 15 | 0.46% | |
RECLTD.NS | Dividend King | 2023-08-14 | Quarterly | 17 | 6.82% | |
KOVAI.NS | Dividend Junior | 2023-08-10 | Annually | 4 | 0.17% | |
EXIDEIND.NS | Dividend Junior | 2023-08-01 | Annually | 22 | 0.76% | |
AMIORG.NS | Dividend Junior | 2023-09-18 | Annually | 3 | 0.15% | |
TASTYBITE.NS | Dividend Junior | 2023-07-14 | Annually | 8 | 0.01% | |
NGIL.NS | No Dividend Player | 2023-09-21 | Annually | 4 | 0.08% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.116 | 1.500 | 7.67 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.224 | 1.500 | 8.62 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 128.03 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 9.89 | 2.00 | 6.70 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 9.89 | 2.00 | 5.06 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.518 | 1.000 | 4.71 | 4.71 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.145 | 1.000 | 9.10 | 9.10 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 4.66 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 92.61 | 1.000 | 0.747 | 0 | [1 - 100] |
returnOnEquityTTM | 0.224 | 2.50 | 9.11 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 9.89 | 2.00 | 6.70 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.310 | 1.500 | 2.25 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 9.89 | 2.00 | 6.70 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -2.73 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0207 | 1.000 | -1.984 | 0 | [0.1 - 0.5] |
Total Score | 2.21 |
AstraZeneca Pharma India
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, distributes, and markets pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease and diabetes medicines under the Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN brands; Respiratory medicines under the Symbicort and FASENRA brand names; and oncology medicines under the LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex brands. The company also offers products in the areas of renal, metabolic, and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators